LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Начало・Списък с акции・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

8.24 -0.96

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.06

Максимум

8.46

Ключови измерители
By Trading Economics
Приходи	-1.1B -722M
Продажби	-250M 156M
P/E Средно за сектора	7.603 50.102
EPS	0.14
Марж на печалбата	-461.478
Служители	435
EBITDA	-968M -702M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+179.74% upside

Дивиденти
By Dow Jones
Следващи печалби	3.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-231M 2.1B
Предишно отваряне	9.2
Предишно затваряне	8.24

Настроения в новините

By Acuity

31%

69%

84 / 344 Класиране в Healthcare

BioCryst Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.06.2026 г., 20:30 ч. UTC

Печалби

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2.06.2026 г., 23:58 ч. UTC

Пазарно говорене

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2.06.2026 г., 23:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.06.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2.06.2026 г., 23:41 ч. UTC

Пазарно говорене

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2.06.2026 г., 23:01 ч. UTC

Придобивния, сливания и поглъщания

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2.06.2026 г., 23:01 ч. UTC

Придобивния, сливания и поглъщания

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2.06.2026 г., 23:00 ч. UTC

Придобивния, сливания и поглъщания

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2.06.2026 г., 22:57 ч. UTC

Пазарно говорене

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2.06.2026 г., 22:50 ч. UTC

Пазарно говорене

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2.06.2026 г., 21:07 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.06.2026 г., 21:07 ч. UTC

Пазарно говорене

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2.06.2026 г., 21:00 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

2.06.2026 г., 20:46 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:38 ч. UTC

Печалби

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2.06.2026 г., 20:21 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:12 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Product Rev $594M

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Adj EPS 85c >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Loss $177M >PANW

Сравнение с други в отрасъла

Ценова промяна

BioCryst Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

179.74% нагоре

12-месечна прогноза

Среден 23.33 USD 179.74%

Висок 32 USD

Нисък 13 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за BioCryst Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на BioCryst Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

84 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.